Susanne B Haga

List of Publications by Year
in descending order

		186265	233421
91	2,343	28	45
papers	citations	h-index	g-index

92	92	92	2767
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clinical Genetics, 2012, 82, 388-394.	2.0	219
2	Public Knowledge of and Attitudes Toward Genetics and Genetic Testing. Genetic Testing and Molecular Biomarkers, 2013, 17, 327-335.	0.7	195
3	Ethical, Legal, and Social Implications of Biobanks for Genetics Research. Advances in Genetics, 2008, 60, 505-544.	1.8	118
4	Impact of limited population diversity of genome-wide association studies. Genetics in Medicine, 2010, 12, 81-84.	2.4	96
5	Insurance Coverage Policies for Personalized Medicine. Journal of Personalized Medicine, 2012, 2, 201-216.	2.5	82
6	Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists. Pharmacogenomics, 2013, 14, 957-968.	1.3	66
7	Pharmacogenetic testing: not as simple as it seems. Genetics in Medicine, 2008, 10, 391-395.	2.4	64
8	Genomic Risk Profiling: Attitudes and Use in Personal and Clinical Care of Primary Care Physicians Who Offer Risk Profiling. Journal of General Internal Medicine, 2011, 26, 834-840.	2.6	64
9	Primary Care Physiciansâ€™ Knowledge, Attitudes, and Experience with Personal Genetic Testing. Journal of Personalized Medicine, 2019, 9, 29.	2.5	58
10	Public Perspectives About Pharmacogenetic Testing and Managing Ancillary Findings. Genetic Testing and Molecular Biomarkers, 2012, 16, 193-197.	0.7	55
11	Translating genomic biomarkers into clinically useful diagnostics. Expert Review of Molecular Diagnostics, 2006, 6, 179-191.	3.1	51
12	Professional Perspectives About Pharmacogenetic Testing and Managing Ancillary Findings. Genetic Testing and Molecular Biomarkers, 2012, 16, 21-24.	0.7	49
13	Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions. Genetics in Medicine, 2011, 13, 723-728.	2.4	47
14	Adding pharmacogenetics information to drug labels: lessons learned. Pharmacogenetics and Genomics, 2006, 16, 847-854.	1.5	46
15	Comparison of delivery strategies for pharmacogenetic testing services. Pharmacogenetics and Genomics, 2014, 24, 139-145.	1.5	43
16	Horizon Scan Of Clinical Laboratories Offering Pharmacogenetic Testing. Health Affairs, 2018, 37, 717-723.	5.2	43
17	Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings. Circulation Genomic and Precision Medicine, 2018, 11, e002228.	3.6	40
18	Patient experiences with pharmacogenetic testing in a primary care setting. Pharmacogenomics, 2016, 17, 1629-1636.	1.3	38

#	Article	IF	Citations
19	Delivering pharmacogenetic testing in a primary care setting. Pharmacogenomics and Personalized Medicine, 2013, 6, 105.	0.7	37
20	Incorporation of pharmacogenetic testing into medication therapy management. Pharmacogenomics, 2015, 16, 1931-1941.	1.3	35
21	Community pharmacistsâ€™ experience with pharmacogenetic testing. Journal of the American Pharmacists Association: JAPhA, 2015, 55, 587-594.	1.5	34
22	Researcher Practices on Returning Genetic Research Results. Genetic Testing and Molecular Biomarkers, 2010, 14, 821-827.	0.7	32
23	Prescribing BiDil. Journal of the American College of Cardiology, 2006, 48, 12-14.	2.8	31
24	Genetically Guided Statin Therapy on Statin Perceptions, Adherence, and Cholesterol Lowering: A Pilot Implementation Study in Primary Care Patients. Journal of Personalized Medicine, 2014, 4, 147-162.	2.5	31
25	Access to Genetic Counselors in the Southern United States. Journal of Personalized Medicine, 2019, 9, 33.	2.5	31
26	Pharmacogenetic testing: current evidence of clinical utility. Therapeutic Advances in Drug Safety, 2013, 4, 155-169.	2.4	30
27	Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting. Pharmacogenomics, 2014, 15, 1677-1686.	1.3	30
28	Teaching resources for genetics. Nature Reviews Genetics, 2006, 7, 223-229.	16.3	29
29	Considerations for the Impact of Personal Genome Information: A Study of Genomic Profiling among Genetics and Genomics Professionals. Journal of Genetic Counseling, 2010, 19, 387-401.	1.6	28
30	Pharmacogenomics courses in pharmacy school curricula. Pharmacogenomics, 2019, 20, 625-630.	1.3	28
31	Challenges of development and implementation of point of care pharmacogenetic testing. Expert Review of Molecular Diagnostics, 2016, 16, 949-960.	3.1	27
32	A stepwise approach to implementing pharmacogenetic testing in the primary care setting. Pharmacogenomics, 2019, 20, 1103-1112.	1.3	27
33	Primary-care physiciansâ€™ access to genetic specialists: anÂimpediment to the routine use of genomic medicine?. Genetics in Medicine, 2013, 15, 513-514.	2.4	26
34	Genomic Counseling: Next Generation Counseling. Journal of Genetic Counseling, 2014, 23, 689-692.	1.6	26
35	Striking a balance in communicating pharmacogenetic test results: Promoting comprehension and minimizing adverse psychological and behavioral response. Patient Education and Counseling, 2014, 97, 10-15.	2.2	25
36	Enhancing geneticistsâ€™ perspectives of the public through community engagement. Genetics in Medicine, 2012, 14, 243-249.	2.4	23

#	Article	IF	Citations
37	Development and Initial Assessment of a Patient Education Video about Pharmacogenetics. Journal of Personalized Medicine, 2017, 7, 4.	2.5	22
38	Primary care providersâ€™ use of pharmacist support for delivery of pharmacogenetic testing. Pharmacogenomics, 2017, 18, 359-367.	1.3	21
39	Defining the spectrum of genome policy. Nature Reviews Genetics, 2006, 7, 966-972.	16.3	20
40	Consideration of patient preferences and challenges in storage and access of pharmacogenetic test results. Genetics in Medicine, 2011, 13, 887-890.	2.4	19
41	Stakeholder Views on Returning Research Results. Advances in Genetics, 2013, 84, 41-81.	1.8	19
42	Challenges to Integrating Pharmacogenetic Testing into Medication Therapy Management. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 346-352.	0.9	19
43	A review of consent practices and perspectives for pharmacogenetic testing. Pharmacogenomics, 2016, 17, 1595-1605.	1.3	17
44	Ethical Issues of Predictive Genetic Testing for Diabetes. Journal of Diabetes Science and Technology, 2009, 3, 781-788.	2.2	16
45	Informationâ€Seeking and Sharing Behavior Following Genomic Testing for Diabetes Risk. Journal of Genetic Counseling, 2015, 24, 58-66.	1.6	16
46	Clinical Utilization of Pharmacogenetics in Psychiatry â€“ Perspectives of Pharmacists, Genetic Counselors, Implementation Science, Clinicians, and Industry. Pharmacopsychiatry, 2020, 53, 162-173.	3.3	16
47	Evaluation of a pharmacogenetic educational toolkit for community pharmacists. Pharmacogenomics, 2016, 17, 1491-1502.	1.3	15
48	Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting. Pharmacogenomics, 2017, 18, 327-335.	1.3	14
49	Educating patients and providers through comprehensive pharmacogenetic test reports. Pharmacogenomics, 2017, 18, 1047-1050.	1.3	14
50	Clinical and Counseling Experiences of Early Adopters of Whole Exome Sequencing. Journal of Genetic Counseling, 2016, 25, 337-343.	1.6	13
51	Awareness of family health history in a predominantly young adult population. PLoS ONE, 2019, 14, e0224283.	2.5	13
52	Characterization of clinical study populations by race and ethnicity in biomedical literature. Ethnicity and Disease, 2012, 22, 96-101.	2.3	13
53	Analysis of Educational Materials and Destruction/Opt-Out Initiatives for Storage and Use of Residual Newborn Screening Samples. Genetic Testing and Molecular Biomarkers, 2010, 14, 587-592.	0.7	12
54	Promoting Public Awareness and Engagement in Genome Sciences. Journal of Genetic Counseling, 2013, 22, 508-516.	1.6	12

#	Article	IF	Citations
55	Nursesâ€™ communication of pharmacogenetic test results as part of discharge care. Pharmacogenomics, 2015, 16, 251-256.	1.3	10
56	Qualitative user evaluation of a revised pharmacogenetic educational toolkit. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 139-146.	0.7	10
57	Toward digital-based interventions for medication adherence and safety. Expert Opinion on Drug Safety, 2020, 19, 735-746.	2.4	9
58	Introducing personalized health for the family: the experience of a single hospital system. Pharmacogenomics, 2017, 18, 1589-1594.	1.3	8
59	Ensuring the Safe Use of Genomic Medicine in Children. Clinical Pediatrics, 2009, 48, 703-708.	0.8	7
60	Integrating pharmacogenetic testing into primary care. Expert Review of Precision Medicine and Drug Development, 2017, 2, 327-336.	0.7	7
61	First Responder to Genomic Information: A Guide for Primary Care Providers. Molecular Diagnosis and Therapy, 2019, 23, 459-466.	3.8	7
62	The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine. Journal of Personalized Medicine, 2021, 11, 45.	2.5	7
63	Revisiting Secondary Information Related to Pharmacogenetic Testing. Frontiers in Genetics, 2021, 12, 741395.	2.3	7
64	Delivering pharmacogenetic testing to the masses: an achievable goal?. Pharmacogenomics, 2014, 15, 1-4.	1.3	6
65	Proposal for a pharmacogenetics certificate program for pharmacists. Pharmacogenomics, 2016, 17, 535-539.	1.3	6
66	Update: looking beyond the 100,000 Genome Project. Personalized Medicine, 2017, 14, 85-87.	1.5	6
67	A Systematic Review of the Scope of Study of mHealth Interventions for Wellness and Related Challenges in Pediatric and Young Adult Populations. Adolescent Health, Medicine and Therapeutics, 2022, Volume 13, 23-38.	0.9	6
68	Patient characteristics, experiences and perceived value of pharmacogenetic testing from a single testing laboratory. Pharmacogenomics, 2019, 20, 581-587.	1.3	5
69	The enduring importance of family health history in the era of genomic medicine and risk assessment. Personalized Medicine, 2020, 17, 229-239.	1.5	5
70	Promoting the participantâ€“researcher partnership. Genetics in Medicine, 2014, 16, 228-230.	2.4	4
71	Interprofessional education for personalized medicine through technology-based learning. Personalized Medicine, 2015, 12, 237-243.	1.5	4
72	Rationale and design of the SLCO1B1 genotype guided statin therapy trial. Pharmacogenomics, 2016, 17, 1873-1880.	1.3	4

#	Article	IF	Citations
73	Managing Increased Accessibility to Pharmacogenomic Data. Clinical Pharmacology and Therapeutics, 2019, 106, 922-924.	4.7	4
74	Pharmacogenomic Testing In Pediatrics: Navigating The Ethical, Social, And Legal Challenges . Pharmacogenomics and Personalized Medicine, 2019, Volume 12, 273-285.	0.7	4
75	100k Genome Project: sequencing and much more. Personalized Medicine, 2013, 10, 761-764.	1.5	3
76	Considerations of pharmacogenetic testing in children. Pharmacogenomics, 2016, 17, 975-977.	1.3	3
77	Independent Community Pharmacistsâ€™ Experience in Offering Pharmacogenetic Testing. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 877-886.	0.7	3
78	Overview of Policy, Ethical and Social Considerations in Genomic and Personalized Medicine. , 2013, , 392-404.		2
79	Potential use of auxiliary labels to promote patient awareness of pharmacogenetic testing. Pharmacogenomics, 2015, 16, 299-301.	1.3	2
80	Evaluating Primary Care Providersâ€™ Readiness for Delivering Genetic and Genomic Services to Underserved Populations. Public Health Genomics, 2021, , 1-10.	1.0	2
81	Conference Scene: Is personalized medicine ready for prime time?. Personalized Medicine, 2012, 9, 475-478.	1.5	1
82	Public Trust in Genomic Risk Assessment for Type 2 Diabetes Mellitus. Journal of Genetic Counseling, 2014, 23, 401-408.	1.6	1
83	Considering the Benefits and Risks of Research Participants' Access to Sequence Data. Genetic Testing and Molecular Biomarkers, 2017, 21, 717-721.	0.7	1
84	Informational Quest. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	1
85	Individualizing pharmacogenomic test results in the context of the microbiome. Personalized Medicine, 2020, 17, 459-468.	1.5	1
86	From Sequence to Genomic Medicine: Genome Policy Considerations. , 2009, , 388-400.		1
87	Promoting Wellness Through Mobile Health Technology in a College Student Population: Protocol Development and Pilot Study. JMIR Research Protocols, 2020, 9, e16474.	1.0	1
88	Genomics-based labeling and attribution: a case for integrating social sciences into personalized medicine research. Personalized Medicine, 2006, 3, 317-323.	1.5	0
89	Genome Policy Considerations for Genomic Medicine. , 2010, , 209-222.		0
90	Foundations and Application of Precision Medicine. , 2019, , 21-45.		0

#	Article	IF	Citations
91	Delivery of Pharmacogenetic Testing with or without Medication Therapy Management in a Community Pharmacy Setting. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 785-796.	0.7	0